MSL Team Management is the fourth module of the 10-part Medical Affairs Product Launch Series. It showcases innovative insights, best practices and benchmarks surrounding MSL teams’ budgets, staffing, activity start times and key performance indicators that occur as part of medical affairs’ contributions to product launch strategy. In developing this module, Cutting Edge Information’s analysts collected surveys from and consulted with a series of medical affairs leaders at several top pharmaceutical, biotechnology and medical device companies.
- Pages: 56
- Metrics: 200+
- Figures: 34
To learn more about the other modules in the Medical Affairs Product Launch Series and the benefits of subscribing to the entire series, click here.
Top Reasons to Buy MSL Team Management (Module 1.4)
Determine when MSL team budgets and staffing should increase during the product lifecycle: Determining MSL headcount depends on many factors, including product needs and the resources available. This module explores the different patterns for the percentage change in MSL staffing throughout the launch window.
Benchmark key performance indicators (KPIs) during the launch window: Although KPIs can be a point of contention among different MSL team leaders, they can be useful for determining how many MSLs a team should employ and how many thought leaders each MSL should engage. Use the data in this module to help your team benchmark their engagement and activity levels.
Understand the interplay between MSL resource and activity levels throughout the product launch window: MSLs are involved early in the product launch window because they are instrumental to building a foundation of HCP engagement and disease state awareness. Through detailed profiles, the module examines how MSL activities shift throughout the launch window based on the product’s needs.
MSL Activity Start
MSL teams are often one of the earliest medical affairs groups to be dispatched to the field. MSLs become involved early because they are instrumental to building a foundation of HCP engagement and disease state awareness. Nevertheless, Figure 1.4.1 [included in full report] shows that 60% of surveyed teams begin MSL involvement during registration and launch.
- Over a quarter (28%) of surveyed teams begin MSL activities during Phase 3a. This stage is an ideal start for many because it gives MSLs ample time to prepare HCPs for an upcoming product and glean important insights about product use, messaging and the competitor landscape to help support the product during launch.
- One surveyed team even begins during Phase 2.
- Another team waits until after the product reaches the market — a late start time given the importance of MSL-HCP early engagement.
Examples of companies that have participated in this study: